UBS AM
RPTX

UBS AM’s Repare Therapeutics RPTX Stock Holding History

UBS AM’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-144,424
Closed -$2.12M – 2708
2022
Q4 		$2.12M Buy
144,424
+22,080
+18% +$330K ﹤0.01% 1499
2022
Q3 		$1.48M Sell
122,344
-18,429
-13% -$237K ﹤0.01% 1751
2022
Q2 		$1.97M Sell
140,773
-5,217
-4% -$61.4K ﹤0.01% 1623
2022
Q1 		$2.08M Sell
145,990
-11,614
-7% -$172K ﹤0.01% 1777
2021
Q4 		$3.32M Sell
157,604
-2,895
-2% -$68.2K ﹤0.01% 1609
2021
Q3 		$4.21M Sell
160,499
-5,520
-3% -$178K ﹤0.01% 1437
2021
Q2 		$5.18M Sell
166,019
-15,672
-9% -$513K ﹤0.01% 1353
2021
Q1 		$5.58M Buy
181,691
+4,948
+3% +$168K ﹤0.01% 1289
2020
Q4 		$6.06M Sell
176,743
-10,526
-6% -$314K ﹤0.01% 1216
2020
Q3 		$5.76M Buy
187,269
+2,535
+1% +$67.1K ﹤0.01% 1101
2020
Q2 		$5.73M Buy
+184,734
New +$5.93M ﹤0.01% 1066

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM's RPTX Position: Q1 2023 in Review

UBS AM sold out of Repare Therapeutics (RPTX) in Q1 2023, closing a stake of 144,424 shares — an estimated $2.12M sold.

UBS AM first reported a position in RPTX in Q2 2020 and held it in 11 quarters. The position peaked at $6.06M in Q4 2020. 77 funds tracked by Wall St. Rank hold RPTX as of Q1 2023.

  • UBS AM reported no remaining Repare Therapeutics position as of Q1 2023 after selling out during the quarter.
  • UBS AM sold 144,424 Repare Therapeutics shares in Q1 2023, an estimated $2.12M.
  • UBS AM first reported a position in Repare Therapeutics in Q2 2020 and held it in 11 quarters.
  • UBS AM's Repare Therapeutics position peaked at $6.06M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.